MacroGenics

MGNX · Nasdaq · United States

Share price · MGNX

$1.97-2.12 (-51.83%) 3M

close as of 2026-11-18 · 24h delayed · vol 720K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MGNX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 23 Oct 2026-38.0%
  2. 29 Sep 2026-7.1%
  3. 28 Sep 2026+8.6%
  4. 14 May 2026+20.6%
  5. 12 May 2026+19.3%
  6. 10 Mar 2026+45.3%
  7. 25 Feb 2026+11.0%
  8. 17 Dec 2025+19.3%

Share of unusual movement by asset

For each asset, the share of MGNX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—42%
Sessions with no dated event—58%

No dated announcements about its assets since 2 Jul 2024.

Assets

(5 total)
5Total Assets
0Approved
0Phase 3 / Filed
5Phase 1–2 / Early
3Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Phase 2
PD-1 x CTLA-4Multispecific antibody
Indication not yet linked
Phase 1
ADAM9Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1
HIV envelope gp120 x CD3Multispecific antibody
HIV
Phase 1
HIV envelope gp41 x CD3Multispecific antibody
HIV
Phase 1
CD123 x CD3Multispecific antibody
Acute Myeloid Leukemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
LorigerlimabPhase 2Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma …
Est. primary completion 2027-07 · NCT06730347 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$19M$31M$49M$20M-$6.3M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$33M$39M$114M—-$41M operating cash flowreport ↗
2026-Q1$21M$35M$67M$37M-$36M operating cash flowreport ↗
2025-Q3$73M$33M$80M—-$30M operating cash flowreport ↗
2025-Q2$22M$41M$131M$36M-$47M operating cash flowreport ↗
2025-Q1$13M$40M$146M$41M-$47M operating cash flowreport ↗
2024-Q3$111M$41M$180M—$60M operating cash flowreport ↗
2024-Q2$11M$52M$84M$56M-$44M operating cash flowreport ↗
2024-Q1$9.1M$46M$80M$52M-$46M operating cash flowreport ↗
2023-Q3$10M$30M$90M—-$35M operating cash flowreport ↗
2023-Q2$13M$43M$109M—-$2.1M operating cash flowreport ↗
2023-Q1$25M$46M$224M$38M-$13M operating cash flowreport ↗
2022-Q3$42M$48M$84M$25M-$9.4M operating cash flowreport ↗
2022-Q2$26M$52M$21M$41M-$49M operating cash flowreport ↗
2022-Q1$11M$61M$47M$66M-$58M operating cash flowreport ↗
2021-Q3$16M$50M$191M$53M-$15M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$150M$147M$57M$19M-$81M operating cash flowreport ↗

MacroGenics reported FY2025 revenue of $149.5M, down 0.3% YoY, with R&D expenses of $147.2M, down 16.9% YoY. The company reported a net loss of $74.6M for the year and held $189.9M in cash, cash equivalents and marketable securities as of December 31, 2025.

Management affirmed cash runway guidance into late 2027 and highlighted upcoming pipeline milestones, including initial Phase 1 data for MGC026 in mid-2026, initial Phase 1 data for MGC028 in the second half of 2026, a Phase 2 LINNET update for lorigerlimab in mid-2026, and an IND submission for MGC030 planned for the third quarter of 2026. The company also noted the FDA’s partial clinical hold on the LINNET study, with no new patients being enrolled while the hold remains in effect.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$150M$177M$183M$17M-$68M operating cash flowreport ↗
2023-FY$59M$167M$101M$2.3M-$78M operating cash flowreport ↗
2022-FY$152M$207M$109M$30M-$87M operating cash flowreport ↗
2021-FY$77M$215M$123M$51M-$144M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($129K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-30Kuriakose Emil · directorAward / grant (derivative)44,000——Form 4
2026-10-30VASCONCELLES MICHAEL · directorAward / grant (derivative)44,000——Form 4
2026-10-30Kuriakose Emil · directorAward / grant (derivative)7,500——Form 4
2026-10-30VASCONCELLES MICHAEL · directorAward / grant (derivative)7,500——Form 4
2026-10-06Bonvini Ezio · Sr VP, Research & CSOOption exercise8,000$2.60$21KForm 4
2026-10-06Bonvini Ezio · Sr VP, Research & CSOOption exercise (derivative)8,000$2.60$21KForm 4
2026-08-19Peters Jeffrey Stuart · Senior VP, GC, and SecretaryOpen-market sale31,105$4.15$129KForm 4
2026-08-17Bonvini Ezio · Sr VP, Research & CSOOption exercise40,000$2.60$104KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 109 reporting institutions held 43.2M shares ($116.2M, 67.8% of shares outstanding).

#InstitutionSharesValue
1ARMISTICE CAPITAL, LLC6,012,000$17.4M
2RENAISSANCE TECHNOLOGIES LLC2,963,559$8.6M
3MILLENNIUM MANAGEMENT LLC2,794,357$8.1M
4VANGUARD CAPITAL MANAGEMENT LLC2,653,853$7.7M
5TWO SIGMA INVESTMENTS, LP2,527,829$7.3M
6BANK OF AMERICA CORP /DE/2,401,814$6.9M
7MARSHALL WACE, LLP2,025,526$5.9M
8RA CAPITAL MANAGEMENT, L.P.1,864,176$5.4M
9WASATCH ADVISORS LP1,559,701$4.5M
10VANGUARD PORTFOLIO MANAGEMENT LLC1,208,775$3.5M
11BlackRock, Inc.1,163,146$3.4M
12D. E. Shaw & Co., Inc.1,058,424$3.1M
13Connor, Clark & Lunn Investment Management Ltd.867,249$2.5M
14CITADEL ADVISORS LLC782,618$2.3M
15GEODE CAPITAL MANAGEMENT, LLC697,321$2.0M